Education
About Us
Working with TipRanks
Follow Us
Armata Pharmaceuticals Inc (ARMP)
:ARMP
ARMP Stock Chart & Stats
$6.40
$0.11(5.39%)
At close: 4:00 PM EST
$6.40
$0.11(5.39%)
Day’s Range― - ―
52-Week Range$0.90 - $16.34
Previous CloseN/A
Volume48.90K
Average Volume (3M)536.86K
Market Cap
$232.28M
Enterprise Value$270.88M
Total Cash (Recent Filing)$14.76M
Total Debt (Recent Filing)$177.68M
Price to Earnings (P/E)―
Beta0.75
Next Earnings
Mar 19, 2026EPS Estimate
-0.28Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.74
Shares Outstanding36,406,906
10 Day Avg. Volume121,090
30 Day Avg. Volume536,864
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)-1.39
Price to Sales (P/S)12.93
P/FCF Ratio-1.70
Enterprise Value/Market Cap1.17
Enterprise Value/Revenue53.60
Enterprise Value/Gross Profit76.07
Enterprise Value/Ebitda-8.92
Forecast
1Y Price Target
$12.00Price Target Upside87.50% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Efficacy EvidencePhase 2 data showing that the lead phage added to standard antibiotics produced better clinical outcomes with no evidence of relapse and a favorable safety profile supports the candidate's potential as a frontline adjunct for difficult Staphylococcus aureus bloodstream infections.
Manufacturing ReadinessCommissioning of an in-house cGMP phage manufacturing facility with successful initial production runs secures operational capacity to support pivotal trials and potential commercial supply, creating a practical advantage over patient-specific approaches.
Regulatory PathwayFDA agreement to advance the lead bacteriophage candidate into a Phase 3 superiority study provides clear regulatory endorsement and reduces uncertainty around an approval pathway.
Bears Say
Liquidity And Dilution RiskLimited cash resources increase the likelihood that additional funding will be required to advance pivotal and follow‑on trials, creating execution risk and potential shareholder dilution.
Pipeline Development DependencyAdvancement of additional indications depends on securing external funding to initiate new trials, which could delay clinical expansion and limit upside if not obtained.
Research Conflict Of InterestBusiness relationships between the covering firm and companies it covers may create conflicts that could affect the objectivity of research reports and influence investor perception of analyst commentary.
Armata Pharmaceuticals News
ARMP FAQ
What was Armata Pharmaceuticals Inc’s price range in the past 12 months?
Armata Pharmaceuticals Inc lowest stock price was $0.90 and its highest was $16.34 in the past 12 months.
What is Armata Pharmaceuticals Inc’s market cap?
Armata Pharmaceuticals Inc’s market cap is $232.28M.
When is Armata Pharmaceuticals Inc’s upcoming earnings report date?
Armata Pharmaceuticals Inc’s upcoming earnings report date is Mar 19, 2026 which is in 60 days.
How were Armata Pharmaceuticals Inc’s earnings last quarter?
Armata Pharmaceuticals Inc released its earnings results on Nov 12, 2025. The company reported -$0.74 earnings per share for the quarter, missing the consensus estimate of -$0.42 by -$0.32.
Is Armata Pharmaceuticals Inc overvalued?
According to Wall Street analysts Armata Pharmaceuticals Inc’s price is currently Undervalued.
Does Armata Pharmaceuticals Inc pay dividends?
Armata Pharmaceuticals Inc does not currently pay dividends.
What is Armata Pharmaceuticals Inc’s EPS estimate?
Armata Pharmaceuticals Inc’s EPS estimate is -0.28.
How many shares outstanding does Armata Pharmaceuticals Inc have?
Armata Pharmaceuticals Inc has 36,406,906 shares outstanding.
What happened to Armata Pharmaceuticals Inc’s price movement after its last earnings report?
Armata Pharmaceuticals Inc reported an EPS of -$0.74 in its last earnings report, missing expectations of -$0.42. Following the earnings report the stock price went down -4.634%.
Which hedge fund is a major shareholder of Armata Pharmaceuticals Inc?
Currently, no hedge funds are holding shares in ARMP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Armata Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$12.00 (87.50% Upside)
$12.00 (87.50% Upside)
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
134.55%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-8.88%
Trailing 12-Months
Company Description
Armata Pharmaceuticals Inc
Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has a partnership agreement with Merck & Co. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Marina del Rey, California.
ARMP Stock 12 Month Forecast
Average Price Target
$12.00
▲(87.50% Upside)
Technical Analysis
Ownership Overview
0.63% Insiders
1.04% Mutual Funds
0.58% Other Institutional Investors
96.88% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---